Filing Analysis
Nika Pharmaceuticals, Inc. terminated its engagement with OLAYINKA OYEBOLA & CO on October 2, 2024, and subsequently engaged Boladale Lawal & Co as its new independent accountant on October 5, 2024.
🚩 Red Flags
- Auditor change triggered by a 'discovery' is a significant red flag for potential internal control or reporting issues.
- Rapid succession of auditor changes (termination and new engagement within 3 days) can indicate friction in financial oversight.
📋 Key Facts
- Termination of previous auditor (OLAYINKA OYEBOLA & CO) occurred on October 2, 2024.
- The company stated that no services had been performed by the outgoing auditor prior to termination.
- New auditor (Boladale Lawal & Co) was engaged on October 5, 2024.
- The dismissal of the previous accountant was based on a 'discovery' made by the company.
Nika Pharmaceuticals, Inc. announced the engagement of a new independent accounting firm, Olayinka Oyebola & Co (Chartered Accountants), to audit its financial statements effective September 23, 2024.
🚩 Red Flags
- Change in certifying accountant (Item 4.01) can sometimes indicate disagreements with previous auditors, though not explicitly stated here.
- Engagement of a 'Chartered Accountants' firm rather than a major US-based CPA firm may signal cost-cutting or potential complexities in auditing standards for US SEC compliance.
📋 Key Facts
- The company engaged OLAYINKA OYEBOLA & CO (Chartered Accountants) on September 23, 2024.
- The new firm will serve as the independent accountant to audit the company's financial statements.
- The filing was signed by CEO Dimitar Slavchev Savov.
Nika Pharmaceuticals, Inc. has announced the cancellation of a previously planned asset acquisition and the simultaneous resignation of its independent accountant. The company is currently without an auditor and is working to find a successor to facilitate the filing of its 10-Q.
🚩 Red Flags
- Unexpected auditor resignation (Item 4.01).
- Cancellation of a major asset acquisition involving an insider/related party (Dimitar Slavchev Savov).
- Loss of ownership in Nika Europe, Ltd. and its physical assets (factory/land) previously disclosed as part of the company's footprint.
- Potential for delayed financial reporting (10-Q) due to lack of an auditor.
📋 Key Facts
- On August 23, 2024, Nika Pharmaceuticals, Inc. effectively cancelled the acquisition of Nika Pharmaceuticals, Ltd., which was originally scheduled for May 9, 2024.
- The company returned 100% ownership of Nika Pharmaceuticals, Ltd. to Dimitar Slavchev Savov, an officer and director.
- As a result of the cancellation, the company no longer owns 99.99% of Nika Europe, Ltd. or the associated factory building and land.
- On August 21, 2024, independent accountant Fruci & Associates II, PLLC tendered its resignation.
- The company is currently searching for a new accounting firm to audit financial statements.
Nika Pharmaceuticals acquired 100% of its Bulgarian subsidiary from the CEO/Director (Dimitar Slavchev Savov) for a nominal value. This transaction results in the parent company gaining ownership of real estate valued at approximately $2.05 million, which was previously owned personally by the CEO.
🚩 Red Flags
- Related-party transaction: The CEO is the seller of the subsidiary and the owner of the assets being transferred to the public company.
- Potential conflict of interest: The CEO personally funded a significant portion ($191,534) of equipment for a company he leads, which may complicate capital structure or future equity implications.
- Valuation risk: While independent evaluators were used for the in-kind contribution, the transfer of personal assets to a public entity at nominal cost is a high-scrutiny event.
📋 Key Facts
- Acquisition of 100% of Nika Pharmaceuticals, Ltd. (Bulgaria) effective May 9, 2024.
- Transaction price for the subsidiary: nominal value of 5,000 BGN.
- The acquisition grants ownership of a production building and land valued at $2,045,209 USD.
- The assets were originally purchased and renovated by CEO Dimitar Savov using personal funds.
- Nika Europe, Ltd. signed a $957,670 supply agreement for GMP-compliant vial production equipment on April 23, 2024.
- CEO Dimitar Savov personally paid the $191,534 down payment for the new production equipment.
Nika Pharmaceuticals completed a merger with Nika BioTechnology, Inc., resulting in the acquisition of an additional 40% stake in Nika Europe Ltd. Additionally, the company's subsidiary acquired four technologies via a transaction funded by an insider.
🚩 Red Flags
- Significant related-party transactions: Dimitar Slavchev Savov is an officer/director/majority shareholder in the parent company, the merging entity (Nika BioTechnology), and holds a 20% stake in the subsidiary (Nika Europe Ltd).
- Insider-funded transaction: The $24,683 technology acquisition was paid for personally by Dimitar Slavchev Savov on behalf of the subsidiary.
- Potential conflict of interest regarding asset valuations and ownership structures across multiple entities controlled by the same individual.
📋 Key Facts
- Completed merger of Nika BioTechnology, Inc. into Nika Pharmaceuticals, Inc. on April 10, 2024.
- Acquired a 40% stake in Nika Europe Ltd., increasing total ownership to 80%.
- Nika Europe Ltd. acquired four technologies (three generic drugs: MENTHYL VALERATE, METAMIZOLE SODIUM, VINPOCETINE; and one dietary supplement) on April 12, 2024.
- The technology acquisition cost was 45,000 BGN (~$24,683 USD).
- Dimitar Slavchev Savov serves as CEO, Director, and majority shareholder of Nika Pharmaceuticals, Inc.
Nika Pharmaceuticals, Inc. completed a market extension merger with Nika BioTechnology, Inc., effective March 1, 2024. The transaction involves a share-for-share exchange where Nika BioTechnology shareholders receive one NKPH common stock for each share of NIKA they own.
🚩 Red Flags
- Related-party concentration: Dimitar Slavchev Savov owns approximately 69% of Nika BioTechnology and 37% of Nika Pharmaceuticals, indicating significant insider control over both merging entities.
- Potential dilution/capital structure change via the increase in authorized Preferred A stock.
📋 Key Facts
- Merger effective date: March 1, 2024.
- Shareholder and Board approval obtained on February 12, 2024.
- Consideration: 1 share of NKPH common stock for each share of NIKA common stock owned by Nika BioTechnology shareholders.
- Amendment to Articles of Incorporation filed March 4, 2024, increasing authorized Preferred A stock from 10,000,000 to 15,000,000 shares.
- Management and Board composition remains unchanged following the merger.
Nika Pharmaceuticals, Inc. announced the dismissal of its independent accountant, B F Borgers CPA PC, and the engagement of Fruci & Associates II, PLLC, effective February 14, 2024.
🚩 Red Flags
- Sudden dismissal of an auditor can sometimes indicate disagreements over accounting principles or reporting, though no specific reason was cited in this filing.
📋 Key Facts
- Dismissal of B F Borgers CPA PC occurred on February 14, 2024.
- Engagement of Fruci & Associates II, PLLC as the new independent accountant for auditing financial statements.
- The Board of Directors authorized the former accountant to respond to inquiries from the successor accountant regarding historical data.